Table 4.
Baseline features related to post-SIRT severe adverse events.
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Sex, male | 0.78 (0.14–8.19) | 1.00 | ||
| Child–Pugh B | 4.92 (1.32–20.74) | 0.01 | 2.48 (0.57–11.84) | 0.28 |
| BCLC stage | 1.56 (0.37–9.40) | 0.77 | ||
| Previous treatment | 2.51 (0.69–9.66) | 0.19 | ||
| Markers of portal hypertension a | 4.81 (0.98–46.82) | 0.05 | 2.34 (0.37–25.68) | 0.53 |
| High visceral adipose radiodensity b | 8.74 (1.78–85.14) | 0.003 | 5.61 (1.05–56.89) | 0.04 |
a Markers of portal hypertension includes splenomegaly, esophageal varices, or thrombocytopenia (platelet count <100,000/mm3). b Defined as visceral adipose radiodensity ≥ −85 HU. ORs and P values were estimated using Exact Logistic Regression. For the BCLC stage, patients in category A were compared to patients in categories B and C.